Amerikanische Gesellschaft für Hirudotherapie

Hepatic Portal Congestion (Non-Cirrhotic, Investigational)

Highly investigational adjunct for non-cirrhotic hepatic congestion; case reports only; cirrhosis and portal hypertension are absolute exclusions.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for hepatic portal congestion. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for systemic portal hypertension is investigational and considered very high-risk.
Welche Evidenz existiert?
Tier C (investigational). No published trials; only theoretical mention. Evidence-based management of portal hypertension and hepatic congestion: treat underlying cirrhosis or hepatic vein obstruction (Budd-Chiari syndrome, congestive hepatopathy from right heart failure), non-selective beta-blockers (propranolol, nadolol) for varices, endoscopic variceal band ligation, TIPS for refractory variceal bleeding or ascites. Leech therapy cannot address systemic portal pressure and risks severe bleeding in patients with varices or coagulopathy.
Hauptrisiken
  • Catastrophic bleeding in patients with esophageal or gastric varices (cirrhosis)
  • Severe bleeding from coagulopathy in cirrhotic patients
  • Bleeding from bite sites for 6 to 24 hours after detachment (markedly prolonged in cirrhosis)
  • Worsening of hepatic encephalopathy from gastrointestinal bleeding
  • Local skin infection or, rarely, Aeromonas infection (high risk with cirrhosis)
  • Allergic reaction to leech saliva (uncommon)
  • Delay of beta-blocker, variceal banding, or TIPS evaluation
  • Risk of spontaneous bacterial peritonitis if leech bites near ascitic fluid
Wer dies nicht in Betracht ziehen sollte
  • Patients with cirrhosis and esophageal varices (absolute contraindication)
  • Patients with thrombocytopenia (platelets <50,000) or INR >1.5 from liver disease
  • Patients with ascites (high infection risk)
  • Patients with hepatic encephalopathy
  • Patients with active or recent gastrointestinal bleeding
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients who have not been managed by a hepatologist
Was Sie Ihren Kliniker fragen sollten
  • Am I being managed by a hepatologist or transplant center?
  • Do I have varices on endoscopy, and have I been offered beta-blocker prophylaxis or banding?
  • What are my platelet count, INR, and Child-Pugh / MELD score?
  • Am I a candidate for TIPS or liver transplantation?
  • What evidence specifically supports leech therapy for portal congestion?
  • What is the bleeding risk for someone with my coagulation status?
  • What is the cost and is it covered by insurance? (typically not covered)
Wann dringende medizinische Versorgung suchen
  • Vomiting blood or passing black tarry stools (variceal bleeding — emergency)
  • Severe abdominal pain with fever (spontaneous bacterial peritonitis)
  • New confusion, sleepiness, or asterixis (hepatic encephalopathy)
  • Rapid abdominal swelling or new ascites
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

Was dies NICHT bedeutet

  • This is NOT FDA-cleared for portal hypertension or hepatic congestion.
  • Theoretical mention does NOT establish safety or efficacy in cirrhotic patients with varices and coagulopathy.
  • Leech therapy CANNOT reduce systemic portal pressure or treat the underlying liver disease.
  • It does NOT substitute for hepatology care, beta-blocker therapy, endoscopic banding, or TIPS evaluation.
  • It does NOT mean leech application is safe in patients with bleeding risk from liver disease — this is one of the highest-risk applications imaginable.

Clinical Profile

Category
gastrointestinal
ICD-10
K76.1, K76.6
Safety tier
high

Evidence Summary

Non-cirrhotic hepatic congestion (most commonly cardiac hepatopathy from right heart failure, or congestive hepatopathy from constrictive pericarditis) is managed by addressing the underlying cardiac pathology. No controlled clinical trial of leech therapy for non-cirrhotic hepatic congestion has been published; use is investigational and mechanistic only, and the honest evidence grade is D. Any local-decongestion rationale is plausible at most as a transient hemodynamic effect and is unproven. This entity is distinct from cirrhotic portal hypertension, which is an absolute contraindication given varices, coagulopathy, and infection risk.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Sotnikov OS et al. (2011)0

Detailed Trial Entries

4 trials indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Cirrhosis or portal hypertension (any cause)
  • Esophageal/gastric varices
  • Coagulopathy from hepatic dysfunction
  • Decompensated heart failure
  • Anticoagulation for cardiac indications

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Hepatic Portal Congestion (Non-Cirrhotic, Investigational) — Hirudotherapy Evidence | ASH